Igarashi, T. | bioRxiv Science

bioRxiv2022

Workflow sharing with automated metadata validation and test execution to improve the reusability of published workflows

BackgroundMany open-source workflow systems have made bioinformatics data analysis procedures portable. Sharing these workflows provides researchers easy access to high-quality analysis methods without the requirement of computational expertise. However, published workflows are not always guaranteed to be reliably reusable. Therefore, a system is needed to lower the cost of sharing workflows in a reusable form. ResultsWe introduce Yevis, a system to build a workflow registry that automatically validates and tests workflows to be published. The validation and test are based on the requirements we defined for a workflow being reusable with confidence. Yevis runs on GitHub and Zenodo and allows workflow hosting without the need of dedicated computing resources. A Yevis registry accepts workflow registration via a GitHub pull request, followed by an automatic validation and test process for the submitted workflow. As a proof of concept, we built a registry using Yevis to host workflows from a community to demonstrate how a workflow can be shared while fulfilling the defined requirements. ConclusionsYevis helps in the building of a workflow registry to share reusable workflows without requiring extensive human resources. By following Yeviss workflow-sharing procedure, one can operate a registry while satisfying the reusable work-flow criteria. This system is particularly useful to individuals or communities that want to share workflows but lacks the specific technical expertise to build and maintain a workflow registry from scratch.

bioinformatics↗

bioRxiv2021

Early Dynamics of Chronic Myeloid Leukemia on Nilotinib Predicts Deep Molecular Response

Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase1,2. ABL1-selective tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML3-7. The ultimate goal of CML treatment is likely to be TKI-free maintenance of deep molecular response (DMR), which is defined by quantitative measurement of BCR-ABL1 transcripts on the international scale (IS)8, and durable DMR is a prerequisite to reach this goal9. Thus, an algorithm to enable the early prediction of DMR achievement on TKI therapy is quite valuable. Here, we show that our mathematical framework based on a clinical trial dataset10 can accurately predict the response to frontline nilotinib. We found that our simple dynamical model can predict nilotinib response by using two common laboratory findings (observation values): IS11,12 and white blood cell (WBC) count. Furthermore, our proposed method identified patients who failed to achieve DMR with high fidelity according to the data collected only at three initial time points during nilotinib therapy. Since our model relies on the general properties of TKI response, our framework would be applicable to CML patients who receive frontline nilotinib or other TKIs in clinical practice. Significance StatementChronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. The goal of this treatment is the sequential achievement of deep molecular response (DMR). Tyrosine kinase inhibitors (TKIs) are effective in the reduction because they inhibit CML cell proliferation. However, because of individual differences in the TKI efficacy, some patients are unable to achieve DMR, so that early prediction of DMR reachability is necessary for personalized medicine. By combining time series analysis and mathematical modeling, we developed a mathematical method that accurately predicts patients who do not achieve DMR in the early stages of TKI administration. Our prediction method gives a basis of effective personalized treatments for CML patients.

systems biology↗